A new trading day began on Tuesday, with Celldex Therapeutics Inc (NASDAQ: CLDX) stock price down -9.31% from the previous day of trading, before settling in for the closing price of $20.29. CLDX’s price has ranged from $14.40 to $47.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43.00% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -33.68%. With a float of $64.70 million, this company’s outstanding shares have now reached $66.37 million.
In an organization with 186 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 65.94%, operating margin of -2778.89%, and the pretax margin is -2248.76%.
Celldex Therapeutics Inc (CLDX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.53%, while institutional ownership is 114.37%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -33.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.38% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Here are Celldex Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 174.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.84 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.71 million. That was inferior than the volume of 0.86 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 43.70%. Additionally, its Average True Range was 1.15.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 27.30%, which indicates a significant increase from 23.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.33% in the past 14 days, which was higher than the 56.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.29, while its 200-day Moving Average is $27.43. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $19.90. Second resistance stands at $21.41. The third major resistance level sits at $22.40. If the price goes on to break the first support level at $17.40, it is likely to go to the next support level at $16.41. Assuming the price breaks the second support level, the third support level stands at $14.90.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
With a market capitalization of 1.22 billion, the company has a total of 66,384K Shares Outstanding. Currently, annual sales are 7,020 K while annual income is -157,860 K. The company’s previous quarter sales were 1,180 K while its latest quarter income was -47,090 K.
